PURPOSE: To compare the receipt of clofarabine plus cytarabine (Clo+Ara-C arm) with cytarabine (Ara-C arm) in patients ≥ 55 years old with refractory or relapsed acute myelogenous leukemia (AML). PATIENTS AND METHODS: Patients were randomly assigned to receive either clofarabine (Clo) 40 mg/m(2) or a placebo followed by Ara-C 1 g/m(2) for five consecutive days. The primary end point was overall survival (OS). Secondary end points included event-free survival (EFS), 4-month EFS, overall remission rate (ORR; complete remission [CR] plus CR with incomplete peripheral blood count recovery), disease-free survival (DFS), duration of remission (DOR), and safety. RESULTS: Among 320 patients with confirmed AML (median age, 67 years), the median OS was 6.6 months in the Clo+Ara-C arm and 6.3 months in the Ara-C arm (hazard ratio [HR], 1.00; 95% CI, 0.78 to 1.28; P = 1.00). The ORR was 46.9% in the Clo+Ara-C arm (35.2% CR) versus 22.9% in the Ara-C arm (17.8% CR; P < .01). EFS (HR: 0.63; 95% CI, 0.49 to 0.80; P < .01) and 4-month EFS (37.7% v 16.6%; P < .01) favored the Clo+Ara-C arm compared with Ara-C arm, respectively. DFS and DOR were similar in both arms. Overall 30-day mortality was 16% and 5% for CLO+Ara-C and Ara-C arms, respectively. In the Clo+Ara-C and Ara-C arms, the most common grade 3 to 4 toxicities were febrile neutropenia (47% v 35%, respectively), hypokalemia (18% v 11%, respectively), thrombocytopenia (16% v 17%, respectively), pneumonia (14% v 10%, respectively), anemia (13% v 0%, respectively), neutropenia (11% v 9%, respectively), increased AST (11% v 2%, respectively), and increased ALT (10% v 3%, respectively). CONCLUSION: Although the primary end point of OS did not differ between arms, Clo+Ara-C significantly improved response rates and EFS. Study follow-up continues, and the role of clofarabine in the treatment of adult patients with AML continues to be investigated.
RCT Entities:
PURPOSE: To compare the receipt of clofarabine plus cytarabine (Clo+Ara-C arm) with cytarabine (Ara-C arm) in patients ≥ 55 years old with refractory or relapsed acute myelogenous leukemia (AML). PATIENTS AND METHODS: Patients were randomly assigned to receive either clofarabine (Clo) 40 mg/m(2) or a placebo followed by Ara-C 1 g/m(2) for five consecutive days. The primary end point was overall survival (OS). Secondary end points included event-free survival (EFS), 4-month EFS, overall remission rate (ORR; complete remission [CR] plus CR with incomplete peripheral blood count recovery), disease-free survival (DFS), duration of remission (DOR), and safety. RESULTS: Among 320 patients with confirmed AML (median age, 67 years), the median OS was 6.6 months in the Clo+Ara-C arm and 6.3 months in the Ara-C arm (hazard ratio [HR], 1.00; 95% CI, 0.78 to 1.28; P = 1.00). The ORR was 46.9% in the Clo+Ara-C arm (35.2% CR) versus 22.9% in the Ara-C arm (17.8% CR; P < .01). EFS (HR: 0.63; 95% CI, 0.49 to 0.80; P < .01) and 4-month EFS (37.7% v 16.6%; P < .01) favored the Clo+Ara-C arm compared with Ara-C arm, respectively. DFS and DOR were similar in both arms. Overall 30-day mortality was 16% and 5% for CLO+Ara-C and Ara-C arms, respectively. In the Clo+Ara-C and Ara-C arms, the most common grade 3 to 4 toxicities were febrile neutropenia (47% v 35%, respectively), hypokalemia (18% v 11%, respectively), thrombocytopenia (16% v 17%, respectively), pneumonia (14% v 10%, respectively), anemia (13% v 0%, respectively), neutropenia (11% v 9%, respectively), increased AST (11% v 2%, respectively), and increased ALT (10% v 3%, respectively). CONCLUSION: Although the primary end point of OS did not differ between arms, Clo+Ara-C significantly improved response rates and EFS. Study follow-up continues, and the role of clofarabine in the treatment of adult patients with AML continues to be investigated.
Authors: M Michallet; X Thomas; J P Vernant; M Kuentz; G Socié; H Espérou-Bourdeau; N Milpied; D Blaise; B Rio; J Reiffers; J P Jouet; J Y Cahn; J H Bourhis; B Lioure; M Leporrier; J J Sotto; G Souillet; L Sutton; P Bordigoni; F Dreyfus; H Tilly; N Gratecos; M Attal; P Y Leprise; F Déméocq; G Michel; A Buzyn; B Delmas-Marsalet; F Bernaudin; N Ifrah; A Sadoun; D Guyotat; M Cavazzana-Cavo; D Caillot; T De Revel; J P Vannier; A Baruchel; N Fegueux; M L Tanguy; A Thiébaut; A Belhabri; E Archimbaud Journal: Bone Marrow Transplant Date: 2000-12 Impact factor: 5.483
Authors: Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: C Karanes; K J Kopecky; D R Head; M R Grever; H E Hynes; E H Kraut; R H Vial; A Lichtin; S Nand; W E Samlowski; F R Appelbaum Journal: Leuk Res Date: 1999-09 Impact factor: 3.156
Authors: R Ohno; T Naoe; A Kanamaru; M Yoshida; A Hiraoka; T Kobayashi; T Ueda; S Minami; Y Morishima; Y Saito Journal: Blood Date: 1994-04-15 Impact factor: 22.113
Authors: Mark R Litzow; Megan Othus; Larry D Cripe; Steven D Gore; Hillard M Lazarus; Sandra J Lee; John M Bennett; Elisabeth M Paietta; Gordon W Dewald; Jacob M Rowe; Martin S Tallman Journal: Br J Haematol Date: 2009-10-05 Impact factor: 6.998
Authors: Nicholas J Short; Hagop Kantarjian; Farhad Ravandi; Xuelin Huang; Lianchun Xiao; Guillermo Garcia-Manero; William Plunkett; Varsha Gandhi; Koji Sasaki; Naveen Pemmaraju; Naval G Daver; Gautam Borthakur; Nitin Jain; Marina Konopleva; Zeev Estrov; Tapan M Kadia; William G Wierda; Courtney D DiNardo; Mark Brandt; Susan M O'Brien; Jorge E Cortes; Elias Jabbour Journal: Leuk Lymphoma Date: 2017-07-18
Authors: Carlos E Vigil; Wei Tan; George Deeb; Sheila N Sait; Annemarie W Block; Petr Starostik; Elizabeth A Griffiths; James E Thompson; Jessica D Greene; Laurie A Ford; Eunice S Wang; Meir Wetzler Journal: Leuk Res Date: 2013-08-15 Impact factor: 3.156
Authors: Farhad Ravandi; Ellen K Ritchie; Hamid Sayar; Jeffrey E Lancet; Michael D Craig; Norbert Vey; Stephen A Strickland; Gary J Schiller; Elias Jabbour; Arnaud Pigneux; Heinz-August Horst; Christian Récher; Virginia M Klimek; Jorge E Cortes; Angelo-Michele Carella; Miklos Egyed; Utz Krug; Judith A Fox; Adam R Craig; Renee Ward; Jennifer A Smith; Gary Acton; Hagop M Kantarjian; Robert K Stuart Journal: Haematologica Date: 2018-05-24 Impact factor: 9.941
Authors: Todd M Cooper; Todd A Alonzo; Robert B Gerbing; John P Perentesis; James A Whitlock; Jeffrey W Taub; Terzah M Horton; Alan S Gamis; Soheil Meshinchi; Michael R Loken; Bassem I Razzouk Journal: Cancer Date: 2014-04-25 Impact factor: 6.860
Authors: J M Middeke; R Herbst; S Parmentier; G Bug; M Hänel; G Stuhler; K Schäfer-Eckart; W Rösler; S Klein; W Bethge; U Bitz; B Büttner; H Knoth; N Alakel; M Schaich; A Morgner; M Kramer; K Sockel; M von Bonin; F Stölzel; U Platzbecker; C Röllig; C Thiede; G Ehninger; M Bornhäuser; J Schetelig Journal: Leukemia Date: 2015-08-18 Impact factor: 11.528
Authors: Tamjeed Ahmed; Scott Holwerda; Heidi D Klepin; Scott Isom; Leslie R Ellis; Susan Lyerly; Megan Manuel; Sarah Dralle; Dmitriy Berenzon; Bayard L Powell; Timothy S Pardee Journal: Leuk Res Date: 2015-06-01 Impact factor: 3.156